NPC2 and nasopharyngeal carcinoma: Investigating the presence of NPC phenotypes in DHDDS cells, where NPC2 function may be impaired, is critical for determining whether these NPC therapies could be repurposed for DHDDS/NUS1 syndrome where there is currently no disease-modifying therapy.